Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med. 2009; 361: 1045-1057
- Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified.Thromb Haemost. May 2011; 105: 752-759
- Drug approval package: Brilinta (tricagrelor) tablets.Medical Review. 2013 ([Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf. Accessed 9 February 2013])
- Drug approval package: Brilinta (tricagrelor) tablets.Statistical Review. 2013 ([Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000StatR.pdf. Accessed 9 February 2013])
- The FDA ticagrelor chemistry review(s).
- The FDA ticagrelor pharmacology review(s).
- The FDA ticagrelor secondary review.www.fda.gov/downloads/AdvisoryCom-mittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAd-visoryCommittee/UCM220192.pdf
- The FDA ticagrelor summary review.
- Ticagrelor NDA letter of approval.
- Ticagrelor FDA, approval issues revisited.Cardiology. 2012; 122: 144-147
- Mortality in the TRACER and ATLAS ACS 2 trials: two more reasons to audit vital records in PLATO.Cardiology. 2012; 123: 11-14
- Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: challenging PLATO mortality rates.Int J Cardiol. Apr 15, 2013; 164: 255-258
- Exploring the reduction in myocardial infarction in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?.Int J Cardiol. May 25, 2013; 165: 396-397
- Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes.Diabetes. 2013; 62: 669-671
- Exploring the ticagrelor-statin interplay in the PLATO trial.Cardiology. 2013; 124: 105-107
- Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports.Ther Adv Cardiovasc Dis. 2013; 7: 5-9
- Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm?.Stroke. 2012; 43: 3409
- Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports.Int J Cardiol. 2013; 168: 633-635